Thomas Facchini

Suggest Changes
Learn More
PURPOSE To evaluate the duration and dose intensity of epirubicin-based regimens in premenopausal patients with lymph node-positive breast cancer. PATIENTS AND METHODS Between 1986 and 1990, 621(More)
599 Background: The combination of E and D has demonstrated clinical objective response rates (ORR) of up to 81% as neoadjuvant therapy for operable BC (Luporsi, ASCO 2000). The RR for D monotherapy(More)